Protocol for the Examination of Specimens From Patients With Carcinomas of the Nasal Cavity and Paranasal Sinuses

Protocol applies to all invasive carcinomas of the nasal cavity and paranasal sinuses. Mucosal malignant melanoma is included. Lymphomas, neuroectodermal neoplasms, and sarcomas are not included.

Based on AJCC/UICC TNM, 7th edition
Protocol web posting date: June 2012

Procedures
• Biopsy
• Resection

Authors
Diane L. Carlson, MD, FCAP*
   Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
Leon Barnes, MD
   Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
John Chan, MD, FCAP
   Department of Pathology, Queen Elizabeth Hospital, Hong Kong
Gary Ellis, DDS
   ARUP Laboratories, Salt Lake City, UT
Louis B. Harrison, MD
   Department of Radiation Oncology, Beth Israel Medical Center, St. Luke’s and Roosevelt Hospitals, New York, NY
Jennifer Leigh Hunt, MD, FCAP
   Department of Pathology, Massachusetts General Hospital, Boston, MA
Mary S. Richardson, MD, DDS
   Department of Pathology, Medical University of South Carolina, Charleston, SC
Jatin Shah, MD, FACS
   Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
Lester D. R. Thompson, MD, FCAP
   Department of Pathology, Southern California Permanente Medical Group, Woodland Hills, CA
Richard Zarbo, MD, DMD, FCAP
   Department of Pathology, Henry Ford Health Systems, Detroit, MI
Bruce M. Wenig, MD, FCAP†
   Department of Pathology and Laboratory Medicine, Beth Israel Medical Center, St. Luke’s and Roosevelt Hospitals, New York, NY

For the Members of the Cancer Committee, College of American Pathologists

* Denotes primary author. † Denotes senior author. All other contributing authors are listed alphabetically.

Previous contributors: Ben Z. Pilch, MD; Elizabeth Gillies, MD; John R. Houck Jr, MD; Kyung-Whan Min, MD; David Novis, MD; Jatin Shah, MD; Richard J. Zarbo, MD, DMD; Bruce M Wenig, MD
© 2012 College of American Pathologists (CAP). All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) Dictation from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) Copying from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a computerized system for items (1) and (2), provided that the Protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from CAP. Applications for such a license should be addressed to the SNOMED Terminology Solutions division of the CAP.

Any public dissemination of the original or modified Protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.
CAP Nasal Cavity, Paranasal Sinuses Protocol Revision History

Version Code
The definition of the version code can be found at www.cap.org/cancerprotocols.

Version: NasalCavityParanasalSinus 3.1.0.1

Summary of Changes
The following changes have been made since the February 2011 release.

Explanatory Notes

Scope of Guidelines
The word “checklist(s)” was changed to “case summary(ies)” or “protocol” as appropriate.
Surgical Pathology Cancer Case Summary

Protocol web posting date: June 2012

NASAL CAVITY AND PARANASAL SINUSES: Incisional Biopsy, Excisional Biopsy, Resection

Select a single response unless otherwise indicated.

Specimen (select all that apply) (Note A)
___ Nasal cavity
   ___ Septum
   ___ Floor
   ___ Lateral wall
   ___ Vestibule
___ Paranasal sinus(es), maxillary
___ Paranasal sinus(es), ethmoid
___ Paranasal sinus(es), frontal
___ Paranasal sinus(es), sphenoid
___ Other (specify): ____________________________
___ Not specified

Received:
___ Fresh
___ In formalin
___ Other (specify): ____________________________

Procedure (select all that apply)
___ Incisional Biopsy
___ Excisional Biopsy
___ Resection (specify type)
   ___ Partial maxillectomy
   ___ Radical maxillectomy
___ Neck (lymph node) Dissection (specify): ____________________________
___ Other (specify): ____________________________
___ Not Specified

+ Specimen Integrity
+ ___ Intact
+ ___ Fragmented

Specimen Size
Greatest dimensions: ___ x ___ x ___ cm
+ Additional dimensions (if more than one part): ___ x ___ x ___ cm

Specimen Laterality (select all that apply)
___ Right
___ Left
___ Bilateral
___ Midline
___ Not specified

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
Tumor Site (select all that apply) (Note A)
___ Nasal cavity
   ___ Septum
   ___ Floor
   ___ Lateral wall
   ___ Vestibule
___ Paranasal sinus(es), maxillary
___ Paranasal sinus(es), ethmoid
___ Paranasal sinus(es), frontal
___ Paranasal sinus(es), sphenoid
___ Other (specify): ________________________
   ___ Not specified

Tumor Focality (select all that apply)
___ Single focus
___ Bilateral
___ Multifocal (specify): ____________________

Tumor Size
Greatest dimension: ___ cm
+ Additional dimensions: ___ x ___ cm
___ Cannot be determined (see Comment)

+ Tumor Description (select all that apply)
+ Gross subtype:
  + ___ Polypoid
  + ___ Exophytic
  + ___ Endophytic
  + ___ Ulcerated
  + ___ Sessile
  + ___ Other (specify): ________________________

+ Macroscopic Extent of Tumor
+ Specify: ________________________

Histologic Type (select all that apply) (Note B)

Carcinomas of the Nasal Cavity and Paranasal Sinuses
___ Squamous cell carcinoma, conventional
   ___ Keratinizing
   ___ Nonkeratinizing (formerly cylindrical cell, transitional cell)

Variants of Squamous Cell Carcinoma
___ Acantholytic squamous cell carcinoma
___ Adenosquamous carcinoma
___ Basaloid squamous cell carcinoma
___ Papillary squamous cell carcinoma
___ Spindle cell squamous cell carcinoma
___ Verrucous carcinoma
__ Giant cell carcinoma
__ Lymphoepithelial carcinoma (non-nasopharyngeal)
__ Sinonasal undifferentiated carcinoma (SNUC)

### Adenocarcinoma, Non-Salivary Gland Type

- **Intestinal type**
  - __ Papillary-type
  - __ Colonic-type
  - __ Solid type
  - __ Mucinous type
  - __ Mixed type
- **Non-intestinal type**
  - __ Low grade
  - __ Intermediate grade
  - __ High grade

### Carcinomas of Minor Salivary Glands

- __ Acinic cell carcinoma
- __ Adenoid cystic carcinoma
- __ Adenocarcinoma, not otherwise specified (NOS)
  - __ Low grade
  - __ Intermediate grade
  - __ High grade
- __ Carcinoma ex pleomorphic adenoma (malignant mixed tumor)
- __ Clear cell adenocarcinoma
- __ Epithelial-myoepithelial carcinoma
- __ Mucoepidermoid carcinoma:
  - __ Low grade
  - __ Intermediate grade
  - __ High grade
- __ Myoepithelial carcinoma (malignant myoepithelioma)
- __ Oncocytic carcinoma
- __ Polymorphous low-grade adenocarcinoma
- __ Salivary duct carcinoma
- __ Other (specify): _____________________________________

### Neuroendocrine Carcinoma

- __ Typical carcinoid tumor (well differentiated neuroendocrine carcinoma)
- __ Atypical carcinoid tumor (moderately differentiated neuroendocrine carcinoma)
- __ Small cell carcinoma (poorly differentiated neuroendocrine carcinoma)
- __ Combined (or composite) small cell carcinoma, neuroendocrine type

- __ Mucosal malignant melanoma

- __ Other (specify): _____________________________________
- __ Carcinoma, type cannot be determined

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
Histologic Grade (Note C)

<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>GX: Cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>G1: Well differentiated</td>
<td></td>
</tr>
<tr>
<td>G2: Moderately differentiated</td>
<td></td>
</tr>
<tr>
<td>G3: Poorly differentiated</td>
<td></td>
</tr>
<tr>
<td>Other (specify)</td>
<td>________________________________________________</td>
</tr>
</tbody>
</table>

Microscopic Tumor Extension

Specify: ____________________________

Margins (select all that apply) (Notes D and E)

<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>Margins uninvolved by invasive carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Distance from closest margin: ___ mm or ___ cm</td>
</tr>
<tr>
<td></td>
<td>Specify margin(s), per orientation, if possible:</td>
</tr>
<tr>
<td>Margins involved by invasive carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Specify margin(s), per orientation, if possible:</td>
</tr>
<tr>
<td>Margins uninvolved by carcinoma in situ (includes moderate and severe dysplasia*) (Note D)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Distance from closest margin: ___ mm or ___ cm</td>
</tr>
<tr>
<td></td>
<td>Specify margin(s), per orientation, if possible:</td>
</tr>
<tr>
<td>Margins involved by carcinoma in situ (includes moderate and severe dysplasia*) (Note D)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Specify margin(s), per orientation, if possible:</td>
</tr>
<tr>
<td>Not applicable</td>
<td></td>
</tr>
</tbody>
</table>

* Applicable only to squamous cell carcinoma and histologic variants.

Treatment Effect (applicable to carcinomas treated with neoadjuvant therapy)

<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not identified</td>
<td></td>
</tr>
<tr>
<td>Present (specify)</td>
<td>________________________________________________</td>
</tr>
<tr>
<td>Indeterminate</td>
<td></td>
</tr>
</tbody>
</table>

Lymph-Vascular Invasion

<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Identified</td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>Indeterminate</td>
<td></td>
</tr>
</tbody>
</table>

Perineural Invasion (Note F)

<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not identified</td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>Indeterminate</td>
<td></td>
</tr>
</tbody>
</table>

Lymph Nodes, Extranodal Extension (Note G)

<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not identified</td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>Indeterminate</td>
<td></td>
</tr>
</tbody>
</table>

Pathologic Staging (pTNM) (Note H)

TNM Descriptors (required only if applicable) (select all that apply)

<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>m (multiple primary tumors)</td>
<td></td>
</tr>
<tr>
<td>r (recurrent)</td>
<td></td>
</tr>
<tr>
<td>y (posttreatment)</td>
<td></td>
</tr>
</tbody>
</table>

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
**Primary Tumor (pT)**

- **pTX**: Cannot be assessed
- **pT0**: No evidence of primary tumor
- **pTis**: Carcinoma in situ

For All Carcinomas Excluding Mucosal Malignant Melanoma

**Primary Tumor (pT): Maxillary Sinus**

- **pT1**: Tumor limited to maxillary sinus mucosa with no erosion or destruction of bone
- **pT2**: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates
- **pT3**: Tumor any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses
- **pT4a**: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribiform plate, sphenoid or frontal sinuses
- **pT4b**: Very advanced local disease. Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V₂), nasopharynx, or clivus

**Primary Tumor (pT): Nasal Cavity and Ethmoid Sinus**

- **pT1**: Tumor restricted to any one subsite, with or without bone invasion
- **pT2**: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bone invasion
- **pT3**: Tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribiform plate
- **pT4a**: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses
- **pT4b**: Very advanced local disease. Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V₂), nasopharynx, or clivus

**Regional Lymph Nodes (pN)** (Notes I through L)

- **pNX**: Cannot be assessed
- **pN0**: No regional lymph node metastasis
- **pN1**: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
- **pN2**: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral nodes, none more than 6 cm in greatest dimension
- **pN2a**: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
- **pN2b**: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
- **pN2c**: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
- **pN3**: Metastasis in a lymph node more than 6 cm in greatest dimension
- **No nodes submitted or found**

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
Number of Lymph Nodes Examined
Specify: __
  + Number cannot be determined (explain): ______________________

Number of Positive Lymph Nodes
Specify: __
  + Number cannot be determined (explain): ______________________
  + Size of the largest positive lymph node: _______ (Note K)
  + Size of the associated metastatic focus: _______ (Note K)
  + Position of the involved node (level): _______ (Note K)

*Metastases at level VII are considered regional lymph node metastases. Midline nodes are considered ipsilateral nodes.

Distant Metastasis (pM)
___ Not applicable
___ pM1: Distant metastasis
  + Specify site(s) if known: ______________________
  + Source of pathologic metastatic specimen (specify): ______________

For Mucosal Malignant Melanoma

Primary Tumor (pT)
___ pT3: Mucosal disease
___ pT4a: Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin
___ pT4b: Very advanced disease. Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures

Regional Lymph Nodes (pN)
___ pNX: Regional lymph nodes cannot be assessed
___ pN0: No regional lymph node metastases
___ pN1: Regional lymph node metastases present

Distant Metastasis (pM)
___ Not applicable
___ pM1: Distant metastasis present
  + Specify site(s), if known: ______________________
  + Source of pathologic metastatic specimen (specify): ______________

+ Additional Pathologic Findings (select all that apply)
+ ____ None identified
+ ____ Carcinoma in situ (Note M)
+ ____ Epithelial dysplasia (Note M)
  + Specify: ______________________
+ ____ Inflammation (specify type): ______________________
+ ____ Squamous metaplasia
+ ____ Epithelial hyperplasia
+ ____ Colonization
  + ____ Fungal
  + ____ Bacterial
+ ____ Other (specify): ______________________
Ancillary Studies (Note N)
+ Specify type(s): __________________________
+ Specify result(s): __________________________

Clinical History (select all that apply)
+ ___ Neoadjuvant therapy
  + ___ Yes (specify type): __________________________
  + ___ No
  + ___ Indeterminate
+ ___ Other (specify): __________________________

Comment(s)
Explanatory Notes

Scope of Guidelines
The reporting of oral cancer including the lip is facilitated by the provision of a case summary illustrating the features required for comprehensive patient care. However, there are many cases in which the individual practicalities of applying such a case summary may not be straightforward. Common examples include finding the prescribed number of lymph nodes, trying to determine the levels of the radical neck dissection, and determining if isolated tumor cells in a lymph node represent metastatic disease. Case summaries have evolved to include clinical, radiographic, morphologic, immunohistochemical, and molecular results in an effort to guide clinical management. Adjuvant and neoadjuvant therapy can significantly alter histologic findings, making accurate classification an increasingly complex and demanding task. This protocol tries to remain simple while still incorporating important pathologic features as proposed by the American Joint Committee on Cancer (AJCC) cancer staging manual, the World Health Organization classification of tumors, the TNM classification, the American College of Surgeons Commission on Cancer, and the International Union on Cancer (UICC). This protocol is to be used as a guide and resource, an adjunct to diagnosing and managing cancers of the oral cavity in a standardized manner. It should not be used as a substitute for dissection or grossing techniques and does not give histologic parameters to reach the diagnosis. Subjectivity is always a factor, and elements listed are not meant to be arbitrary but are meant to provide uniformity of reporting across all the disciplines that use the information. It is a foundation of practical information that will help to meet the requirements of daily practice to benefit both clinicians and patients alike.

A. Anatomical Sites and Subsites for the Nasal Cavity and Paranasal Sinuses (Figure 1)
The nasal cavity is divided in the midline to right and left halves by the septum; each half opens on the face via the nares or nostrils and communicates behind with the nasopharynx through the posterior nasal apertures or the choanae. The nasal cavity is divided into 4 subsites including the septum, floor, lateral wall, and vestibule. The paranasal sinuses represent a grouping of 4 paired sinuses including the maxillary sinuses, ethmoid sinuses, frontal sinuses, and sphenoid sinuses. The nasoethmoidal complex is divided into 2 sites including the nasal cavity and the ethmoid sinuses.

Cancers of the maxillary sinuses are the most common sinonasal malignancies followed by cancers of the ethmoid sinuses, which are much less common.1 Cancers of the frontal and sphenoid sinuses are rare. When considering the nasal cavity and paranasal sinuses, 60% of malignant neoplasms originate from the maxillary sinus, 20% to 30% from the nasal cavity, 10% to 15% from the ethmoid sinus and 1% from the sphenoid and frontal sinuses.2 When only considering the paranasal sinuses, 77% of malignant neoplasms originate from the maxillary sinus, 22% from the ethmoid sinus, and 1% from the sphenoid and frontal sinuses.2

The location as well as the extent of the mucosal lesion in the maxillary sinus has prognostic importance. Ohngren’s line, connecting the medial canthus of the eye to the angle of the mandible, divides the maxillary sinus into an anteroinferior portion (infrastructure) and superioposterior portion (suprastructure) structures. Carcinomas of the infrastructure are associated with a good prognosis; carcinomas of the suprastructure are associated with a poor prognosis. The poorer prognosis with carcinomas of the suprastructure reflects early access of these tumors to critical structures, including the eye, skull base, pterygoids, and infratemporal fossa.1

B. Histological Type

A modification of the World Health Organization (WHO) classification of carcinomas of the nasal cavity and paranasal sinuses is shown below. This list may not be complete. This protocol applies only to carcinomas and melanomas and does not apply to lymphomas, sarcomas or neuroectodermal tumors (eg, olfactory neuroblastoma, primitive neuroectodermal tumor [PNET], others).

Nasal Cavity and Paranasal Sinuses

- Squamous Cell Carcinoma, Conventional
  - Keratinizing
  - Nonkeratinizing (formerly cylindrical cell, transitional cell)
- Variants of Squamous Cell Carcinoma (in alphabetical order)
  - Acantholytic squamous cell carcinoma
  - Adenosquamous carcinoma
  - Basaloid squamous cell carcinoma
  - Papillary squamous cell carcinoma
  - Spindle cell squamous cell carcinoma
  - Verrucous carcinoma
- Giant cell carcinoma*
- Lymphoepithelial carcinoma (non-nasopharyngeal)
- Sinonasal undifferentiated carcinoma (SNUC)
Adenocarcinoma, Non-Salivary Gland Type

Intestinal-type
Non-intestinal type

Carcinomas of Minor Salivary Glands

Acinic cell carcinoma
Adenoid cystic carcinoma
Adenocarcinoma, not otherwise specified (NOS)
Carcinoma ex pleomorphic adenoma (malignant mixed tumor)
Clear cell adenocarcinoma
Mucoepidermoid carcinoma:
Epithelial-myoepithelial carcinoma
Myoepithelial carcinoma (malignant myoepithelioma)
Oncocytic carcinoma
Polymorphous low-grade adenocarcinoma
Salivary duct carcinoma
Other

Neuroendocrine Carcinoma

Typical carcinoid tumor (well differentiated neuroendocrine carcinoma)
Atypical carcinoid tumor (moderately differentiated neuroendocrine carcinoma)
Small cell (undifferentiated) carcinoma (poorly differentiated neuroendocrine carcinoma)
Combined (or composite) small cell carcinoma, neuroendocrine type**

Mucosal Malignant Melanoma

* Not included in WHO classification.

** Represents a carcinoma showing combined features of small cell neuroendocrine carcinoma associated with a squamous or adenocarcinomatous component.4

C. Histologic Grade

For histlogic types of carcinomas that are amenable to grading, 3 histlogic grades are suggested, as shown below. When a tumor manifests more than 1 grade of differentiation, the surgical report must designate both the highest and the most prevalent tumor grades.5,6

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>Cannot be assessed</td>
</tr>
<tr>
<td>1</td>
<td>Well differentiated</td>
</tr>
<tr>
<td>2</td>
<td>Moderately differentiated</td>
</tr>
<tr>
<td>3</td>
<td>Poorly differentiated</td>
</tr>
</tbody>
</table>

This grading system does not apply to all salivary gland tumors. The histologic (microscopic) grading of salivary gland carcinomas has been shown to be an independent predictor of behavior and plays a role in optimizing therapy.7-11 Further, there is often a positive correlation between histologic grade and clinical stage. For the majority of salivary gland carcinomas there is only a single histologic grade and classification alone determines the histologic grade (eg, acinic cell carcinoma is a histologically low-grade carcinoma; salivary duct carcinoma is a histologically high-grade carcinoma). With some exceptions, histologic grading is predicated on cytomorphologic features. In this histologic grading scheme, 3 histologic grades are suggested, as follows:

Grade 1  Well differentiated = Low-grade
Grade 2  Moderately differentiated = Intermediate-grade
Grade 3  Poorly differentiated = High-grade  
Grade X  Cannot be assessed

When a tumor manifests more than 1 grade of differentiation, the surgical report must designate both the highest and the most prevalent tumor grades. In some carcinomas, histologic grading may be based on growth pattern, such as in adenoid cystic carcinoma, for which a histologic high-grade variant has been recognized based on the percentage of solid growth. Those adenoid cystic carcinomas showing 30% or greater of solid growth pattern are considered to be histologically high-grade carcinomas. The histologic grading of mucoepidermoid carcinoma includes a combination of growth pattern characteristics (eg, cystic, solid, neurotropism) and cytomorphologic findings (eg, anaplasia, mitoses, necrosis).

D. Surgical Margins
Reporting of surgical margins should include information regarding the distance of invasive carcinoma, carcinoma in situ or high grade dysplasia (moderate to severe) from the surgical margin. Closeness of the above, microscopically less than 5 mm, from the surgical border should be noted in the report. Presence of the above lesions found within 5 mm of the surgical border carry a significant risk for subsequent local recurrence. Reporting of surgical margins for carcinomas of the minor salivary glands should follow those used for squamous cell carcinoma of oral cavity. There is no category of carcinoma in situ relative to carcinomas of salivary glands (major, minor).

Unlike the oral cavity and larynx, intraepithelial dysplasias including nonkeratinizing and keratinizing dysplasias as well as carcinoma in situ of the nasal cavity and paranasal sinuses are uncommon, especially as an isolated clinical and/or histopathologic lesion. In the sinonasal tract, when carcinoma in situ is identified, it usually is seen in association with an invasive carcinoma. In this setting, the same criteria detailed in the oral cavity and laryngeal protocols apply (see Protocol for the Examination of Specimens from Patients with Carcinomas of the Lip and Oral Cavity and Protocol for the Examination of Specimens from Patients with Carcinomas of the Larynx).

E. Orientation of Specimen
Complex specimens should be examined and oriented with the assistance of attending surgeons. Direct communication between the surgeon and pathologist is a critical component in specimen orientation and proper sectioning. Whenever possible, the tissue examination request form should include a drawing of the resected specimen showing the extent of the tumor and its relation to the anatomic structures of the region. The lines and extent of the resection can be depicted on preprinted adhesive labels and attached to the surgical pathology request forms.

F. Perineural Invasion
The presence of perineural invasion (neurotropism) is an important predictor of poor prognosis in head and neck cancer of virtually all sites. The presence of perineural invasion (neurotropism) in the primary cancer is associated with poor local disease control and regional control, as well as being associated with metastasis to regional lymph nodes. Further, perineural invasion is associated with decrease in disease-specific survival and overall survival. There is conflicting data relative to an association between the presence of perineural invasion and the development of distant metastasis with some studies showing an increased association with distant metastasis but other studies not showing any correlation with distant metastasis. The relationship between perineural invasion and prognosis is independent of nerve diameter. Although perineural invasion of small unnamed nerves may not produce clinical symptoms, the reporting of perineural invasion includes nerves of all sizes including small peripheral nerves (ie, less than 1 mm in diameter). Aside from the impact on prognosis, the presence of perineural invasion also guides therapy. Concurrent adjuvant chemoradiation therapy has been shown to improve outcomes in patients with perineural invasion (as well as in patients with
extranodal extension and bone invasion). Given the significance relative to prognosis and treatment, perineural invasion is a required data element in the reporting of head and neck cancers.

G. Extranodal Extension
The status of cervical lymph nodes is the single most important prognostic factor in aerodigestive cancer. All macroscopically negative or equivocal lymph nodes should be submitted in toto. Grossly positive nodes may be partially submitted for microscopic documentation of metastasis. Reporting of lymph nodes containing metastasis should include whether there is presence or absence of extranodal extension (EE). This finding consists of extension of metastatic tumor, present within the confines of the lymph node, through the lymph node capsule into the surrounding connective tissue, with or without associated stromal reaction. If macroscopic examination suggests EE, this tissue should be submitted for microscopic confirmation. EE is a predictor of regional relapse and a criterion for postoperative radiotherapy.

H. TNM and Stage Groupings
The protocol recommends the TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) for nasal cavity and paranasal sinus cancer. Of note in the 7th edition of the AJCC staging of head and neck cancers is the division of T4 lesions into T4a (moderately advanced local disease) and T4b (very advanced local disease), leading to the stratification of stage IV into stage IVA (moderately advanced local/regional disease), stage IVB (very advanced local/regional disease), and stage IVC (distant metastatic disease).

The 7th edition of the AJCC staging of head and neck cancers includes mucosal malignant melanomas. Approximately two-thirds of mucosal malignant melanomas arise in the sinonasal tract, one-quarter are found in the oral cavity and the remainder occur only sporadically in other mucosal sites of the head and neck. Even small cancers behave aggressively with high rates of recurrence and death. To reflect this aggressive behavior, primary cancers limited to the mucosa are considered T3 lesions. Advanced mucosal melanomas are classified as T4a and T4b. The anatomic extent criteria to define moderately advanced (T4a) and very advanced (T4b) disease are given below. The AJCC staging for mucosal malignant melanomas does not provide for the histologic definition of a T3 lesion; as the majority of mucosal malignant melanomas are invasive at presentation, mucosal based melanomas (T3 lesions) include those lesions that involve either the epithelium and/or lamina propria of the involved site. Rare examples of in situ mucosal melanomas occur but in situ mucosal melanomas are excluded from staging, as they are extremely rare.

For All Carcinomas Excluding Mucosal Malignant Melanoma

<table>
<thead>
<tr>
<th>Primary Tumor: Maxillary Sinus</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
</tr>
<tr>
<td>T0</td>
</tr>
<tr>
<td>Tis</td>
</tr>
<tr>
<td>T1</td>
</tr>
<tr>
<td>T2</td>
</tr>
<tr>
<td>T3</td>
</tr>
<tr>
<td>T4a</td>
</tr>
<tr>
<td>T4b</td>
</tr>
</tbody>
</table>

Primary Tumor: Nasal Cavity and Ethmoid Sinus
Background Documentation

Head and Neck • Nasal Cavity, Paranasal Sinuses

NasalCavityParanasalSinus 3.1.0.1

TX Cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor restricted to any one subsite, with or without bone invasion
T2 Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bone invasion
T3 Tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate
T4a Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses
T4b Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus

Regional Lymph Nodes*
NX Cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
N2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral nodes, none more than 6 cm in greatest dimension
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
N3 Metastasis in a lymph node more than 6 cm in greatest dimension

* Metastases at level VII are considered regional lymph node metastases. Midline nodes are considered ipsilateral nodes.

Distant Metastasis
M0 No distant metastasis
M1 Distant metastasis

For Mucosal Malignant Melanoma

Primary Tumor
T3 Mucosal disease
T4a Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin
T4b Very advanced disease. Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures

Regional Lymph Nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases present

Distant Metastasis
M0 No distant metastasis
M1 Distant metastasis present
By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**Stage Groupings – For All Cancers Except Mucosal Malignant Melanoma**

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T1</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0,N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVA</td>
<td>T1,T2,T3</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4a</td>
<td>N0,N1,N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVB</td>
<td>T4b</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVC</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

**Stage Groupings – For Mucosal Malignant Melanoma**

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage III</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVA</td>
<td>T4a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3-T4a</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVB</td>
<td>T4b</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVC</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y” and “r” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.
**Additional Descriptors**

**Residual Tumor (R)**
Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.

- **RX** Presence of residual tumor cannot be assessed
- **R0** No residual tumor
- **R1** Microscopic residual tumor
- **R2** Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

**I. Classification of Neck Dissection**
1. Radical neck dissection
2. Modified radical neck dissection, internal jugular vein and/or sternocleidomastoid muscle spared
3. Selective neck dissection (SND), as specified by the surgeon
   a. Supraomohyoid neck dissection
   b. Posterolateral neck dissection
   c. Lateral neck dissection
   d. Central compartment neck dissection
4. Selective neck dissection (SND), as specified by the surgeon -“SND” with levels and sublevels designated (Figure 2).
5. Extended radical neck dissection, as specified by the surgeon

**J. Regional Lymph Nodes (pN0): Isolated Tumor Cells**
Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. Lymph nodes or distant sites with ITCs found by either histologic examination, immunohistochemistry, or non-morphologic techniques (eg, flow cytometry, DNA analysis, polymerase chain reaction [PCR] amplification of a specific tumor marker) should be classified as N0 or M0, respectively. Specific denotation of the assigned N category is suggested as follows for cases in which ITCs are the only evidence of possible metastatic disease.

- **pN0** No regional lymph node metastasis histologically, no examination for isolated tumor cells (ITCs)
- **pN0(i-)** No regional lymph node metastasis histologically, negative morphologic (any morphologic technique, including hematoxylin-eosin and immunohistochemistry) findings for ITCs
- **pN0(i+)** No regional lymph node metastasis histologically, positive morphologic (any morphologic technique, including hematoxylin-eosin and immunohistochemistry) findings for ITCs
- **pN0(mol-)** No regional lymph node metastasis histologically, negative non-morphologic (molecular) findings for ITCs
- **pN0(mol+)** No regional lymph node metastasis histologically, positive non-morphologic (molecular) findings for ITCs

For purposes of pathologic evaluation, lymph nodes are organized by levels as shown in Figure 2.
In order for pathologists to properly identify these nodes, they must be familiar with the terminology of the regional lymph node groups and with the relationships of those groups to the regional anatomy. Which lymph node groups surgeons submit for histopathologic evaluation depends on the type of neck dissection they perform. Therefore, surgeons must supply information on the types of neck dissections that they perform and the details of the local anatomy in the specimens they submit for examination or, in other manners, orient those specimens for pathologists.

If it is not possible to assess the levels of lymph nodes (for instance, when the anatomic landmarks in the excised specimens are not specified), then the lymph node levels may be estimated as follows: level II, upper third of internal jugular (IJ) vein or neck specimen; level III, middle third of IJ vein or neck specimen; level IV, lower third of IJ vein or neck specimen, all anterior to the sternocleidomastoid muscle.

**Level I. Submental Group (Sublevel IA)**
Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone.

**Level I. Submandibular Group (Sublevel IB)**
Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle and the body of the mandible. The submandibular gland is included in the specimen when the lymph nodes within this triangle are removed.

**Level II. Upper Jugular Group (Sublevels IIA and IIB)**
Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve extending from the level of the carotid bifurcation (surgical landmark) or hyoid bone (clinical landmark) to the skull base. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the stylohyoid muscle.
Level III. Middle Jugular Group
Lymph nodes located around the middle third of the internal jugular vein extending from the carotid bifurcation superiorly to the omohyoid muscle (surgical landmark), or cricothyroid notch (clinical landmark) inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

Level IV. Lower Jugular Group
Lymph nodes located around the lower third of the internal jugular vein extending from the omohyoid muscle superiorly to the clavicle inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

Level V. Posterior Triangle Group (Sublevels VA and VB)
This group comprises predominantly the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes are also included in this group. The posterior boundary of the posterior triangle is the anterior border of the trapezius muscle, the anterior boundary of the posterior triangle is the posterior border of the sternocleidomastoid muscle, and the inferior boundary of the posterior triangle is the clavicle.

Level VI. Anterior (Central) Compartment
Lymph nodes in this compartment include the pre- and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerve. The superior boundary is the hyoid bone, the inferior boundary is the suprasternal notch, the lateral boundaries are the common carotid arteries and the posterior boundary by the prevertebral fascia.

Level VII. Superior Mediastinal Lymph Nodes
Metastases at level VII are considered regional lymph node metastases; all other mediastinal lymph node metastases are considered distant metastases.

Lymph node groups removed from areas not included in the above levels, eg, scalene, suboccipital, and retropharyngeal, should be identified and reported from all levels separately. Midline nodes are considered ipsilateral nodes.

K. Lymph Nodes

Lymph Node Number
Histological examination of a selective neck dissection specimen will ordinarily include 6 or more lymph nodes. Histological examination of a radical or modified radical neck dissection specimen will ordinarily include 10 or more lymph nodes in the untreated neck.

Measurement of Tumor Metastasis
The cross-sectional diameter of the largest metastasis in a lymph node containing metastatic tumor is measured in the gross specimen at the time of macroscopic examination or, if necessary, on the histologic slide at the time of microscopic examination. There is conflicting data in the literature on the significance of the size of the largest metastatic lymph node on the risk of regional recurrence and a predictor of poor overall survival. While the diameter of the largest positive lymph node may potentially serve as a predictor of outcome, it may not represent an independent predictor of outcome when other pathologic factors are considered.

L. Special Procedures for Lymph Nodes
At the current time, no additional special techniques should be used other than routine histology for the assessment of nodal metastases. Immunohistochemistry and PCR to detect isolated tumor cells are considered investigational techniques at this time.
M. Dysplasia of the Upper Aerodigestive Tract (UADT)
Epithelial dysplasias of the nasal cavity and paranasal sinuses as a precursor lesion for sinonasal carcinomas are less common and less well defined as compared to epithelial dysplasias of the oral cavity and the larynx. Further, unlike dysplastic lesions of the oral cavity and/or the larynx, precursor lesions of the nasal cavity and paranasal sinuses are generally asymptomatic and therefore are not biopsied. Instead, they are identified more often in association with another lesion, such as an invasive carcinoma.

N. Ancillary Studies
At the current time, no additional special techniques are required other than routine histology for the assessment of nasal cavity and paranasal sinus carcinomas. Immunohistochemistry and in situ hybridization (ISH) to detect the presence of viruses (eg, human papillomavirus, Epstein-Barr virus) are considered investigational techniques at this time.

References


